A Phase II Study on Dose Optimization of Fruquintinib in Elderly mCRC Patients Refractory to Standard Treatment（DOFEMCRC）

This is a prospective, multi-center, single arm, phase II study. In this study, the low-dose initial dose incremental optimization scheme was used in the first cycle in patients ≥65 years old who need to receive fruquintinib. The aim is to observe the safety, tolerability and efficacy of fruquintinib in elderly patients with mCRC refractory to standard treatment. The correlation between the efficacy, toxicity and geriatric evaluation of fruquintinib will also be analysed.

Inclusion criteria

• 65 years and older;
• Histologically or cytologically confirmed unresectable metastatic colorectal cancer refractory to or unfit for standard therapies;
• ECOG PS 0-1;
• At least 4 weeks after the last anti-tumor therapy (chemotherapy, radiotherapy, biotherapy or hormone therapy) and more than 3 months after operation treatment before enrollment;
• Life expectancy ≥ 3 months;
• Cooperative in observation of adverse events and curative effect;
• No other anti-tumor concomitant treatment (including steroid drugs);
• Adequate organ and bone marrow functions;
• At least one measurable lesion(s);
• Signed the written informed consent and completed the geriatric questionnaire (G8 screening form) at the time of enrollment.

Exclusion criteria

• Active upper gastrointestinal ulcer, obvious vomiting, chronic diarrhea, intestinal obstruction, absorption disorder, etc which may affect drug absorption, distribution, metabolism, or clearance;
• Evidence of central nervous system metastasis;
• One of the following complications: uncontrolled hypertension, coronary artery disease, arrhythmia and heart failure;
• Abuse of alcohol or drugs;
• Less than 4 weeks from the last clinical trial;
• Previous treatment with VEGFR inhibitors;
• Severe uncontrolled disability with concurrent infection;
• Proteinuria ≥ 2 + (1.0g / 24hr);
• Uncontrollable gastrointestinal bleeding;
• Arterial / venous thromboembolic events such as cerebrovascular accident (including transient ischemic attack) occurred within 12 months before the first dose;
• Acute myocardial infarction, acute coronary syndrome or coronary artery bypass grafting occurred within 6 months before the first dose;
• Fracture or wound that has not been cured for a long time;
• Coagulation dysfunction, bleeding tendency or receiving anticoagulation treatment;
• Congenital or acquired immune deficiency (such as HIV infection), or active hepatitis (HBV DNA ≥ 103copies / ml after regular antiviral therapy);
• Patients who are not suitable for the study judged by the researchers.